skip to content
Drug discovery in Japan : investigating the sources of innovation Preview this item
ClosePreview this item
Checking...

Drug discovery in Japan : investigating the sources of innovation

Author: Sadao Nagaoka
Publisher: Singapore : Springer, 2019.
Edition/Format:   eBook : Document : EnglishView all editions and formats
Summary:
This book analyzes the drug-discovery process in Japan, based on detailed case studies of 12 groups of 15 innovative drugs. It covers the first statin in the world up to the recent major breakthrough in cancer therapy, the recent immune checkpoint inhibitor, the scientific discovery for which a 2018 Nobel Prize in Physiology or Medicine was awarded to Prof. Tasuku Honjo, Kyoto University. The book shows the  Read more...
Rating:

(not yet rated) 0 with reviews - Be the first.

Subjects
More like this

Find a copy online

Links to this item

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Genre/Form: Electronic books
Additional Physical Format: Print version:
Nagaoka, Sadao
Drug Discovery in Japan : Investigating the Sources of Innovation
Singapore : Springer Singapore Pte. Limited,c2019
Material Type: Document, Internet resource
Document Type: Internet Resource, Computer File
All Authors / Contributors: Sadao Nagaoka
ISBN: 9789811389061 9811389063
OCLC Number: 1125265464
Notes: Includes index.
Description: 1 online resource (xv, 333 pages) : illustrations (some color)
Contents: Foreword --
Acknowledgement --
Chapter 1: Introduction --
Chapter 2: Compactin --
Chapter 3: Pravastatin (Pravachol, Mevalotin) --
Chapter 4: Rosuvastatin(Crestor) --
Chapter 5: Leuprorelin (Leuplin, Lupron, Viadur) --
Chapter 6: Oflaxacin and levofloxacin (Tarivid/Cravit) --
Chapter 7: Tamsulosin (Harnal, Flomax, OMNIC) --
Chapter 8: Pranlukast (Onon) --
Chapter 9: Tacrolimus (Prograf) --
Chapter 10: Pioglitazone (Actos, Glustin) --
Chapter 11: Donepezil (Aricept) --
Chapter 12: Candesartan (Blopress, Atacand) --
Chapter 13: Tocilizumab (Actemra,Ro-actemra) --
Chapter 14: Nivolumab (Opdivo) --
Chapter 15: Sources of innovation of drug discovery in Japan and its implications.
Responsibility: Sadao Nagaoka, editor.

Abstract:

The book shows the pervasive high uncertainty in drug discovery: frequent occurrences of unexpected difficulties, discontinuations, serendipities, and good luck, significantly because drug discovery  Read more...

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.

Similar Items

Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


Primary Entity

<http://www.worldcat.org/oclc/1125265464> # Drug discovery in Japan : investigating the sources of innovation
    a schema:MediaObject, schema:CreativeWork, schema:Book ;
    bgn:translationOfWork <http://www.worldcat.org/title/-/oclc/1125265464#CreativeWork/unidentifiedOriginalWork> ;
    library:oclcnum "1125265464" ;
    library:placeOfPublication <http://id.loc.gov/vocabulary/countries/si> ;
    schema:about <http://dewey.info/class/615.19/e23/> ;
    schema:about <http://experiment.worldcat.org/entity/work/data/9607325469#Topic/drug_development> ; # Drug development
    schema:about <http://experiment.worldcat.org/entity/work/data/9607325469#Topic/drug_development_japan> ; # Drug development--Japan
    schema:about <http://experiment.worldcat.org/entity/work/data/9607325469#Place/japan> ; # Japan.
    schema:bookFormat schema:EBook ;
    schema:datePublished "2019" ;
    schema:description "This book analyzes the drug-discovery process in Japan, based on detailed case studies of 12 groups of 15 innovative drugs. It covers the first statin in the world up to the recent major breakthrough in cancer therapy, the recent immune checkpoint inhibitor, the scientific discovery for which a 2018 Nobel Prize in Physiology or Medicine was awarded to Prof. Tasuku Honjo, Kyoto University. The book shows the pervasive high uncertainty in drug discovery: frequent occurrences of unexpected difficulties, discontinuations, serendipities, and good luck, significantly because drug discovery starts when the underlying science is incomplete. Thus, there exist dynamic interactions between scientific progress and drug discovery. High uncertainty also makes the value of an entrepreneurial scientist high. Such scientists fill the knowledge gaps by absorbing external scientific progress and by relentless pursuit of possibilities through their own research, often including unauthorized research, to overcome crises. Further, high uncertainty and its resolution significantly characterize the evolution of competition in the drug industry. The patent system promotes innovation under high uncertainty not only by enhancing appropriability of R&D investment but also by facilitating the combination of knowledge and capabilities among different firms through disclosure. Understanding such a process significantly benefits the creation of innovation management and policy practices."@en ;
    schema:description "Foreword -- Acknowledgement -- Chapter 1: Introduction -- Chapter 2: Compactin -- Chapter 3: Pravastatin (Pravachol, Mevalotin) -- Chapter 4: Rosuvastatin(Crestor) -- Chapter 5: Leuprorelin (Leuplin, Lupron, Viadur) -- Chapter 6: Oflaxacin and levofloxacin (Tarivid/Cravit) -- Chapter 7: Tamsulosin (Harnal, Flomax, OMNIC) -- Chapter 8: Pranlukast (Onon) -- Chapter 9: Tacrolimus (Prograf) -- Chapter 10: Pioglitazone (Actos, Glustin) -- Chapter 11: Donepezil (Aricept) -- Chapter 12: Candesartan (Blopress, Atacand) -- Chapter 13: Tocilizumab (Actemra,Ro-actemra) -- Chapter 14: Nivolumab (Opdivo) -- Chapter 15: Sources of innovation of drug discovery in Japan and its implications."@en ;
    schema:editor <http://experiment.worldcat.org/entity/work/data/9607325469#Person/nagaoka_sadao> ; # Sadao Nagaoka
    schema:exampleOfWork <http://worldcat.org/entity/work/id/9607325469> ;
    schema:genre "Electronic books"@en ;
    schema:inLanguage "en" ;
    schema:isSimilarTo <http://worldcat.org/entity/work/data/9607325469#CreativeWork/drug_discovery_in_japan_investigating_the_sources_of_innovation> ;
    schema:name "Drug discovery in Japan : investigating the sources of innovation"@en ;
    schema:productID "1125265464" ;
    schema:url <http://public.eblib.com/choice/PublicFullRecord.aspx?p=5968658> ;
    schema:url <https://ezproxy.lau.edu.lb:2443/login?url=https://doi.org/10.1007/978-981-13-8906-1> ;
    schema:url <http://public.eblib.com/choice/PublicFullRecord.aspx?p=5968253> ;
    schema:url <https://doi.org/10.1007/978-981-13-8906-1> ;
    schema:workExample <http://worldcat.org/isbn/9789811389061> ;
    schema:workExample <http://dx.doi.org/10.1007/978-981-13-8906-1> ;
    umbel:isLike <http://bnb.data.bl.uk/id/resource/GBB9I4373> ;
    wdrs:describedby <http://www.worldcat.org/title/-/oclc/1125265464> ;
    .


Related Entities

<http://experiment.worldcat.org/entity/work/data/9607325469#Person/nagaoka_sadao> # Sadao Nagaoka
    a schema:Person ;
    schema:familyName "Nagaoka" ;
    schema:givenName "Sadao" ;
    schema:name "Sadao Nagaoka" ;
    .

<http://experiment.worldcat.org/entity/work/data/9607325469#Topic/drug_development_japan> # Drug development--Japan
    a schema:Intangible ;
    schema:name "Drug development--Japan"@en ;
    .

<http://worldcat.org/entity/work/data/9607325469#CreativeWork/drug_discovery_in_japan_investigating_the_sources_of_innovation>
    a schema:CreativeWork ;
    rdfs:label "Drug Discovery in Japan : Investigating the Sources of Innovation" ;
    schema:description "Print version:" ;
    schema:isSimilarTo <http://www.worldcat.org/oclc/1125265464> ; # Drug discovery in Japan : investigating the sources of innovation
    .

<http://worldcat.org/isbn/9789811389061>
    a schema:ProductModel ;
    schema:isbn "9811389063" ;
    schema:isbn "9789811389061" ;
    .


Content-negotiable representations

Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.